Timeline
Last
$407.83
+17.81 (4.57%)
24HR+4.6%
1W+5.2%
1M+11.3%
1Y+35.9%
Valuation
- Market Cap
- $220.1B
- Enterprise Value
- $255.8B
- P/E (TTM)
- 25.32x
- Forward P/E
- 17.40x
- Price / Sales
- 5.91x
- EV / EBITDA
- 15.12x
Cash Flow
- Operating Cash Flow
- $10.8B
- Free Cash Flow
- $7.4B
- FCF Margin
- 20.0%
- Cash Conversion
- 69.1%
- Cash / Share
- $22.3
Margins & Growth
- Gross Margin
- 71.4%
- Operating Margin
- 33.8%
- EBITDA Margin
- 45.5%
- Net Margin
- 21.0%
- Revenue Growth
- 5.8%
- Earnings Growth
- 4.4%
Balance Sheet
- Total Cash
- $12B
- Total Debt
- $57.3B
- Net Cash
- -$45.3B
- Debt / Equity
- 6.24x
- Current Ratio
- 1.26x
- Quick Ratio
- 0.85x
Returns & Ownership
- Return on Assets
- 8.3%
- Return on Equity
- 101.3%
- Dividend Yield
- 2.6%
- Payout Ratio
- 60.9%
- Beta
- 0.41
- Institutional Ownership
- 85.1%
Latest EPS$5.15+0.1% surprise
Beat rate100%4 print streak
Avg surprise+0.1%vs consensus
Next printNov 3, 2026EPS $5.62
Quarterly EPS vs consensus
4 quarters Actual ConsensusLabels: beat $ · YoY %Revisions 14 up / 31 down
Earnings transcripts
Read management commentary and analyst Q&A.
No transcript dates are available yet for this ticker.
Forward estimates
Consensus expectations and estimate momentum.
PeriodEPSRevenueGrowth
0QJun 2026
$5.62$9.4B-6.7%+1QSep 2026
$5.76$9.7B+2.1%0YDec 2026
$22.35$37.7B+2.3%+1YDec 2027
$23.44$38.7B+4.9%Primary research
Recent company filings
Jump directly to earnings releases, quarterly reports, and material updates.
10-QPeriodic Financial Reports2026-08-058-KCorporate Changes & Voting Matters2026-08-048-KCorporate Changes & Voting Matters2026-07-318-KCorporate Changes & Voting Matters2026-05-208-KCorporate Changes & Voting Matters2026-05-1910-QPeriodic Financial Reports2026-05-018-KCorporate Changes & Voting Matters2026-04-308-KCorporate Changes & Voting Matters2026-04-228-KCorporate Changes & Voting Matters2026-02-198-KCorporate Changes & Voting Matters2026-02-038-KCorporate Changes & Voting Matters2026-01-3010-QPeriodic Financial Reports2025-11-05
AMGN stock research · Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; X…
| Last price | $407.8 |
|---|---|
| Day change | +17.81 (4.57%) |
| Market cap | $220.1B |
| P/E (TTM) | 25.32x |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |